Roche partners on a slate of Jnana's immunology, neurology targets, rewarding its faith in the SLC transporter class
When Jnana Therapeutics launched in late 2017 with $50 million in the bank, the biotech billed itself as the first to focus solely and systematically on the solute carrier, or SLC transporter, family — a class of membrane proteins that transport metabolites in and out of cells.
To this day, it’s still the only game in town. But Roche is now jumping on board as a partner to explore some of these targets, with an eye to immune-mediated and neurological diseases. The collaboration starts small at $40 million, but can add up to $1 billion if and as the pharma partner commits to develop the programs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.